A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

August 21, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

July 31, 2028

Conditions
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Interventions
DRUG

ICP-248

Eligible patients will receive ICP-248 orally as per the protocol

Trial Locations (29)

100919

RECRUITING

Peking University Third Hospital, Beijing

130021

NOT_YET_RECRUITING

The First Hospital of Jilin University, Changchun

200032

NOT_YET_RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

210036

NOT_YET_RECRUITING

Jiangsu Province Hospital, Nanjing

230022

NOT_YET_RECRUITING

The First Affiliated Hospital of Anhui Medical University, Hefei

250012

NOT_YET_RECRUITING

Qilu Hospital of Shandong University, Jinan

250021

NOT_YET_RECRUITING

Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan

250117

NOT_YET_RECRUITING

Shandong Cancer Hospital, Jinan

266003

NOT_YET_RECRUITING

The Affiliated Hospital of Qingdao University, Qingdao

300020

NOT_YET_RECRUITING

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

310000

NOT_YET_RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

330006

NOT_YET_RECRUITING

The First Affiliated Hospital of Nanchang University, Nanchang

350001

NOT_YET_RECRUITING

Fujian Medical University Union Hospital, Fuzhou

400016

NOT_YET_RECRUITING

The First Affiliated Hospital of Chongqing Medical University, Chongqing

400030

NOT_YET_RECRUITING

Chongqing University Cancer Hospital, Chongqing

410000

NOT_YET_RECRUITING

Hunan Cancer Hospital, Changsha

421001

NOT_YET_RECRUITING

The First Affiliated Hospital of University of South China, Hengyang

430022

NOT_YET_RECRUITING

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

450000

NOT_YET_RECRUITING

Henan Cancer Hospital, Zhengzhou

450003

NOT_YET_RECRUITING

Henan Provincial People's Hospital, Zhengzhou

451191

NOT_YET_RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

510050

NOT_YET_RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

510080

NOT_YET_RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

530012

NOT_YET_RECRUITING

Guangxi Medical University Cancer Hospital, Nanning

610041

NOT_YET_RECRUITING

West China Hospital of Sichuan University, Chengdu

610072

NOT_YET_RECRUITING

Sichuan Provincial People's Hospital, Chengdu

644000

NOT_YET_RECRUITING

The Second People's Hospital of Yibin, Yibin

710004

NOT_YET_RECRUITING

The Second Affiliated Hospital of Xi'an Jiaotong University, Xian

830000

NOT_YET_RECRUITING

The Affiliated Cancer Hospital of Xinjiang Medical University, Xinjiang

All Listed Sponsors
lead

Beijing InnoCare Pharma Tech Co., Ltd.

INDUSTRY

NCT07082686 - A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | Biotech Hunter | Biotech Hunter